MedTech Dive’s newsletter offers a comprehensive insight into the evolving landscape of Medicare payments for diabetes technology, ensuring you stay up-to-date with industry developments.
A recent proposal by the Centers for Medicare and Medicaid Services (CMS) has stirred discussions among medtech executives, particularly regarding the potential impact on payment methods for diabetes devices. The proposal aims to introduce competitive bidding for insulin pumps and shift payment structures from upfront purchases to monthly rental schedules if implemented.
Insulet and Tandem Diabetes Care, key players in the insulin pump market, are closely monitoring the proposed changes. While Insulet and Tandem do not foresee significant business disruptions, industry analysts anticipate varying impacts on different companies based on their existing business models. For instance, companies like Insulet, Dexcom, and Abbott, which already operate on a monthly bundle basis, may experience less disruption compared to others.
Tandem’s CFO expressed optimism that the proposed changes could potentially drive more individuals towards pump therapy, despite the company’s expectation of minimal business impact. The shift in reimbursement models from traditional Medicare to a pay-as-you-go structure could prompt strategic adjustments in business operations, such as the shift towards pharmacy channel sales for certain pump supplies.
Despite Tandem’s revised earnings forecast for 2025 and recent challenges such as a product recall, the company remains actively engaged in the regulatory process, anticipating final rulings by November. Similarly, Insulet is confident in its resilient sales approach through the pharmacy channel, expecting continued growth and emphasizing the benefits of its Omnipod 5 technology in enhancing diabetes care.
Dexcom, another significant player in the diabetes technology market, has also addressed concerns over the CMS competitive bidding proposal. With a considerable portion of its business tied to fee-for-service Medicare, Dexcom is focused on ensuring uninterrupted access to care for Medicare beneficiaries. As the bidding process is not expected to commence before 2027, the company is preparing to navigate potential regulatory changes in the coming years.
Key Takeaways:
– CMS’s proposed changes in Medicare payments for diabetes technology could impact industry players differently based on their existing business models.
– Companies like Insulet, Dexcom, and Abbott, operating on monthly bundle sales, may experience less disruption compared to others.
– Tandem and Insulet are actively monitoring the proposed changes and remain optimistic about their business resilience and growth prospects.
– Dexcom is committed to ensuring continued access to care for Medicare beneficiaries amidst potential regulatory shifts in the future.
Stay informed with MedTech Dive’s newsletter for the latest updates on the evolving landscape of diabetes technology and Medicare payments.
Tags: sterilization
Read more on medtechdive.com